866-997-4948(US-Canada Toll Free)

Microbiome-Targeted Therapeutics in Immunology

Published By :

GlobalData

Published Date : Mar 2018

Category :

Pharmaceutical

No. of Pages : 78 Pages

Microbiome-Targeted Therapeutics in Immunology

Summary

Flares in gastrointestinal and dermatology indications are characterized by a shift in the proportion of bacterial species in either the gut or skin microbiome. This report focuses on the development of therapies targeting the skin microbiome for the treatment of acne, atopic dermatitis and psoriasis and on the development of therapies targeting the gut microbiome for the treatment of Crohns disease, ulcerative colitis, and irritable bowel syndrome.

Scope

This report combines key opinion leader and payer insight with in-house analyst expertise to provide an insight-rich look at the microbiome space in immunology. Components of the report include -
- Overview of the Gut and Skin Microbiome: microbial dysbiosis by indication
- Epidemiology Overview: prevalent or diagnosed prevalent cases by indication for the 16MM
- Pipeline Assessment: promising late-stage products and early-stage pipeline by indication
- Key Players: leading industry companies by indication
- Clinical Trials Mapping and Design: trial breakdown by phase/indication and trial design by inidcation
- Fecal Microbiota Transplants: opportunities and challenges for gastrointestinal indications
- Pricing, Reimbursement and Regulatory Stategy: US payer perspective on late-stage therapies
- Market Outlook: market potential estimation of late-stage therapies and key launch dates

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global microbiome market in immunology.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Gain insights to help plan and design your clinical trials.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Identify key pricing and reimbursement strategies.
1 Table of Contents
1. Introduction
1.1 Related Reports 6
1.2 Upcoming Related Reports 7
2. Executive Summary 8
2.1 Key Findings 9
2.2 KOL and Payer Insight on Microbiome Competitive Landscape 10
3. Overview of the Gut and Skin Microbiome 11
3.1 Microbiome of the Skin 13
3.2 Microbiome in Atopic Dermatitis 14
3.3 Microbiome in Acne 15
3.4 Microbiome in Psoriasis 16
3.5 Microbiome of the Gut 17
3.6 Microbiome in Inflammatory Bowel Disease 18
3.7 Microbiome in Irritable Bowel Syndrome 19
4. Epidemiology Analysis 20
4.1 Epidemiology Analysis - Acne Vulgaris 22
4.2 Epidemiology Analysis - Atopic Dermatitis 23
4.3 Epidemiology Analysis - Psoriasis 24
4.4 Epidemiology Analysis - Crohns Disease 25
4.5 Epidemiology Analysis - Ulcerative Colitis 26
4.6 Epidemiology Analysis - Irritable Bowel Syndrome 27
5. Pipeline Assessment 28
5.1 Overview of the Development of Pipeline Therapies 30
5.2 Pipeline Assessment - The Gut Microbiome 31
5.3 Qu Biologics QBECO-SSI 33
5.4 Synthetic Biologics SYN-010 35
5.5 Pipeline Assessment - The Skin Microbiome 36
5.6 AOBiomes B-244 38
5.7 Matrisys Biosciences MSB-01 40
6. Key Players 41
6.1 Key Players - Companies Targeting the Microbiome 43
6.2 Analysis of Company Portfolio Gap - Gut Microbiome 44
6.3 Analysis of Company Portfolio Gap - Skin Microbiome 45
7. Clinical Trial Mapping and Design 46
7.1 Clinical Trial Mapping and Design - Gut Microbiome 48
7.2 Clinical Trial Mapping and Design - Skin Microbiome 50
8. Fecal Microbiota Transplants 52
8.1 Is Fecal Microbiota Transplant a Viable Option? 54
8.2 Clinical Trial Mapping and Design 55
9. Pricing, Reimbursement, and Regulatory Strategy 56
9.1 US Strategies for Gastrointestinal Indications 58
9.2 Payer Perspective on QBECO-SSI 59
9.3 Payer Perspective on SYN-010 60
9.4 US Strategies for Dermatology Indications 61
9.5 Payer Perspective on B-244 62
9.6 Payer Perspective on MSB-01 63
10. Market Outlook 64
10.1 Market Outlook for AOBiomes B-244 66
10.2 Market Outlook for Synthetic Biologics SYN-010 67
10.3 Market Outlook for Qu Biologics QBECO-SSI 68
10.4 Key Launch Dates for Pipeline Therapies 69
11. Appendix 70
11.1 Sources 71
11.2 Methodology 72
11.3 Primary Research 73
11.4 About the Authors 74
11.5 About GlobalData 76
11.6 Contact Us 77
11.7 Disclaimer 78

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *